Compare Novartis with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs WYETH LTD - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS WYETH LTD NOVARTIS/
WYETH LTD
 
P/E (TTM) x 512.3 27.7 1,848.1% View Chart
P/BV x 29.7 5.3 555.6% View Chart
Dividend Yield % 1.5 1.3 120.8%  

Financials

 NOVARTIS   WYETH LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
WYETH LTD
Mar-13
NOVARTIS/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs7581,044 72.6%   
Low Rs579818 70.8%   
Sales per share (Unadj.) Rs228.4298.6 76.5%  
Earnings per share (Unadj.) Rs31.757.2 55.4%  
Cash flow per share (Unadj.) Rs32.858.4 56.1%  
Dividends per share (Unadj.) Rs10.0017.00 58.8%  
Dividend yield (eoy) %1.51.8 81.9%  
Book value per share (Unadj.) Rs297.1249.5 119.1%  
Shares outstanding (eoy) m24.6922.72 108.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.1 93.8%   
Avg P/E ratio x21.116.3 129.5%  
P/CF ratio (eoy) x20.415.9 128.0%  
Price / Book Value ratio x2.23.7 60.3%  
Dividend payout %31.529.7 106.1%   
Avg Mkt Cap Rs m16,50521,157 78.0%   
No. of employees `0000.70.5 135.8%   
Total wages/salary Rs m1,445400 361.3%   
Avg. sales/employee Rs Th8,441.313,787.4 61.2%   
Avg. wages/employee Rs Th2,163.6813.0 266.1%   
Avg. net profit/employee Rs Th1,173.12,643.3 44.4%   
INCOME DATA
Net Sales Rs m5,6396,783 83.1%  
Other income Rs m1,718353 487.3%   
Total revenues Rs m7,3577,136 103.1%   
Gross profit Rs m-631,617 -3.9%  
Depreciation Rs m2527 95.1%   
Interest Rs m556 1,005.5%   
Profit before tax Rs m1,5751,938 81.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m792632 125.2%   
Profit after tax Rs m7841,301 60.3%  
Gross profit margin %-1.123.8 -4.6%  
Effective tax rate %50.332.6 154.0%   
Net profit margin %13.919.2 72.5%  
BALANCE SHEET DATA
Current assets Rs m9,5226,984 136.3%   
Current liabilities Rs m3,2962,056 160.3%   
Net working cap to sales %110.472.6 152.0%  
Current ratio x2.93.4 85.0%  
Inventory Days Days3799 36.9%  
Debtors Days Days2824 118.7%  
Net fixed assets Rs m46244 18.8%   
Share capital Rs m123227 54.3%   
"Free" reserves Rs m7,2135,441 132.6%   
Net worth Rs m7,3365,668 129.4%   
Long term debt Rs m025 0.0%   
Total assets Rs m11,1057,901 140.6%  
Interest coverage x29.5353.3 8.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.9 59.1%   
Return on assets %7.616.5 45.7%  
Return on equity %10.722.9 46.6%  
Return on capital %22.234.0 65.3%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m6115 398.7%   
Fx outflow Rs m3,6302,677 135.6%   
Net fx Rs m-3,570-2,662 134.1%   
CASH FLOW
From Operations Rs m1,610923 174.4%  
From Investments Rs m687317 216.8%  
From Financial Activity Rs m-2,677-481 556.4%  
Net Cashflow Rs m-380759 -50.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.1 146.8%  
Indian inst/Mut Fund % 2.0 11.3 17.7%  
FIIs % 1.6 7.2 22.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 30.4 70.7%  
Shareholders   41,647 21,978 189.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  ABBOTT INDIA  FULFORD INDIA  DR. REDDYS LAB  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 1,921 Points Higher; Banking and Auto Stocks Witness Huge Buying(Closing)

Share markets in India jumped sharply today after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 20, 2019 03:35 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - BIOCON COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS